#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16458	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2195	745.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1680	1680	T	925	T,G	850,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16458	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2195	745.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1414	1414	C	948	C	880	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3519	838.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1597	1597	A	985	A,G	913,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3519	838.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2231	2231	C	944	C,A	862,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3519	838.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2305	2305	A	928	A	861	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3519	838.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2857	2857	C	927	C	855	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2396	folP	855	855	100.0	folP.l6.c17.ctg.1	1400	170.0	1	SNP	p	R229S	1	.	.	685	687	AGC	940	942	AGC	244;245;244	A;G;C,A,G	226;228;224,1,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5864	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3357	174.1	1	SNP	p	S91F	1	.	.	271	273	TTC	569	571	TTC	216;217;215	T;T;C	201;204;204	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5864	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3357	174.1	1	SNP	p	D95G	1	.	.	283	285	GGC	581	583	GGC	204;209;212	G;G,A;C	190;193,1;196	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5864	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3357	174.1	1	SNP	p	G95N	0	.	.	283	285	GGC	581	583	GGC	204;209;212	G;G,A;C	190;193,1;196	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1950	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1203	160.9	1	SNP	p	G45D	0	.	.	133	135	GGC	414	416	GGC	236;234;235	G;G;C	212;209;208	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	952	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1011	93.7	0	.	n	.	0	A197.	DEL	197	197	A	641	641	A	226	A	210	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1381	1383	GTC	217;217;217	G;T;C	196;193;195	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	1	SNP	p	D86N	0	.	.	256	258	GAC	487	489	GAC	205;209;212	G;A;C	188;186;194	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	1	SNP	p	R87W	0	.	.	259	261	CGT	490	492	CGT	214;215;213	C;G;T	195;195;193	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	1	SNP	p	S87R	1	.	.	259	261	CGT	490	492	CGT	214;215;213	C;G;T	195;195;193	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	1	SNP	p	R87I	0	.	.	259	261	CGT	490	492	CGT	214;215;213	C;G;T	195;195;193	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5572	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2813	197.0	1	SNP	p	S88P	0	.	.	262	264	TCC	493	495	TCC	212;208;209	T;C;C,T	192;194;195,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5140	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2496	204.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1282	1284	TGC	222;218;219	T;G;C	202;197;198	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5140	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2496	204.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1492	1494	GGC	238;235;235	G;G;C	219;215;213	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1278	1280	GCA	257;255;255	G;C;A	238;235;238	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1281	1283	ATC	260;261;260	A;T;C	243;244;243	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1293	1295	GTG	267;263;260	G;T;G	253;247;245	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1293	1295	GTG	267;263;260	G;T;G	253;247;245	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1797	1799	ACC	231;231;229	A;C;C	214;214;212	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1851	1853	GCG	227;227;229	G;C;G	197;185;196	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1851	1853	GCG	227;227;229	G;C;G	197;185;196	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1974	1976	GGC	197;198;201	G;G;C	180;179;185	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1983	1985	GGC	196;196;193	G;G;C	180;178;178	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4540	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2351	192.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2001	2003	TCG	191;191;189	T,G;C,G;G,T	130,8;152,1;156,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6566	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2957	221.1	0	.	p	.	0	E418G	NONSYN	1252	1254	GAG	1544	1546	GGG	234;232;232	G;G;G	212;212;214	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6566	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2957	221.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1553	1555	CCG	237;234;234	C;C;G	214;215;210	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2686	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1694	157.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	471	471	C	199	C	179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	382	384	GAA	246;248;250	G;A,G;A	229;230,1;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	670	672	GAT	267;268;272	G;A;T	243;244;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	793	795	TCA	292;292;288	T;C,A;A	270;268,1;267	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	922	924	GTC	254;255;252	G;T;C	239;233;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1252	1254	GCA	234;232;234	G;C,A;A	217;216,1;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	0	.	p	.	0	G329S	NONSYN	985	987	GGC	1255	1257	AGC	240;241;240	A;G;C	221;221;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	1	SNP	p	G120K	1	.	.	358	360	AAG	628	630	AAG	258;257;257	A;A;G	243;238;239	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	1	SNP	p	A121D	1	.	.	361	363	GAC	631	633	GAC	255;255;253	G;A;C	238;234;231	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3134	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1446	214.2	1	SNP	p	D121N	0	.	.	361	363	GAC	631	633	GAC	255;255;253	G;A;C	238;234;231	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11916	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4789	248.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1917	1919	AAT	252;254;252	A;A;T	234;237;235	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1376	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1093	125.3	1	SNP	p	V57M	1	.	.	169	171	ATG	533	535	ATG	294;298;299	A;T,C,A;G,A	269;271,1,1;269,2	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
